Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series CAMBRIDGE, Mass. , May 14, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable

CAMBRIDGE, Mass. , May 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call and

- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy - Preliminary data from early patient cohorts in the

Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19 Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and expansion trial in HNSCC Immuno-STAT™ Platform for autoimmune disease featured in Merck presentation

CAMBRIDGE, Mass. , March 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call

CAMBRIDGE, Mass. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Cowen &

Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models CAMBRIDGE, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of

CAMBRIDGE, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr.

CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the publication of research

Presentation Highlights Recent Platform Development Providing the Potential to Readily Exchange T cell Epitopes to Target Diverse T cell Populations CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel